Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3984 - Everyday life with Long-term Chemotherapy Induced Peripheral Neuropathy among Patient in Adjuvant Treatment for Colorectal Cancer – a Multi Methods Study


30 Sep 2019


Poster Display session 3


Marlene Jensen


Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276


M. Jensen1, M. Yilmaz2, B. Pedersen3

Author affiliations

  • 1 Oncology Unit, Aalborg Universitetshospital - Region Nordjylland, 9000 - Aalborg/DK
  • 2 Department Of Oncology, Aalborg University hospital, 9000 - Aalborg/DK
  • 3 Depart. Of Oncology, Aalborg Universitetshospital - Region Nordjylland, 9000 - Aalborg/DK


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3984


Studies describe that up to 90 % of all patients develop chemotherapy induced peripheral neuropathy (CIPN) during and after treatment for colorectal cancer with the chemotherapeutic drug oxaliplatin. Patients may struggle with CIPN many years after treatment completion, and in worst case live with it permanently with deep impact on their everyday life. Until date, there is no treatment to prevent or treat CIPN. Thus, it is urgent to understand the influence of CIPN and detect early signs of this side effect. Still, no golden standard method of assessment and evaluation of CIPN exists. The study aims to answer: 1. What questionnaire is deemed suitable by patients and nurses regarding reporting and sharing the experience of side effects during and after oxaliplatin treatment? 2. How does chemotherapy CIPN progresses and impact everyday life among patients receiving oxaliplatin from initiation of adjuvant chemotherapy until 3 years follow up? 3. How do patients experience and cope with CIPN and how does it influence on their perception of body and self in everyday life during and after adjuvant chemotherapy for colorectal cancer?


The study applies a multi-methods design. To ensure the practicability and meaningfulness of the questionnaire, the questionnaire are chosen in collaboration with patients and nurses in the clinical setting. Two questionnaires are tested; functional assessment of cancer treatment gynecological oncology group neurotoxicity (FACT/GOG-Ntx) and Oxaliplatin associated neurotoxicity questionnaire (OANQ). To explore a more precise and a common understanding and perception of the grade of CIPN, a three-year follow up with the chosen questionnaires will be conducted. The patients’ experiences of side effects are explored within a phenomenological frame of reference and individual in-depth interviews.


The study contributes to identification of early and late signs of CIPN and provides insight into the challenges patients experience. It may assist healthcare providers to address the specific needs of these patients.


The study is ongoing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Marlene Ægidiussen Jensen.


The Novo Nordisk Foundation - Nursing research.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.